SCHEMBL5772064

SCHEMBL5772064

Cc1c(O)cc2cc(C(=O)O)oc2c1C

nearest known ligand 0.46

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 10/20 0.46
GPR35 Q9HC97 3/20 0.45
KDM4E B2RXH2 1/20 0.42
KMT2A Q03164 1/20 0.42
HCAR2 Q8TDS4 1/20 0.39
APEX1 P27695 1/20 0.38
PIM2 Q9P1W9 5/20 0.37
LMNA P02545 1/20 0.36
TP53 P04637 1/20 0.36
DAO P14920 1/20 0.36
THRA P10827 1/20 0.36
THRB P10828 1/20 0.36
CSNK2A1 P68400 3/20 0.35
CSNK2A2 P19784 2/20 0.35
CSNK2B P67870 2/20 0.35
CSNK2A3 Q8NEV1 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5771570 0.86 LMNA (0.47) PIM1GPR35KDM4EKMT2ALMNA
SCHEMBL5770807 0.81 MAPT (0.46) PIM1GPR35KDM4EKMT2ALMNA
SCHEMBL6292875 0.79 MCL1 (0.49) PIM1GPR35KDM4EKMT2AAPEX1
SCHEMBL5768892 0.77 PDE7B (0.41) GPR35KDM4EKMT2ALMNA
SCHEMBL11741038 0.76 DAO (0.46) PIM1GPR35KDM4EKMT2ALMNA
SCHEMBL27843491 0.76 PIM1 (0.51) PIM1GPR35KDM4EKMT2AAPEX1
SCHEMBL5772217 0.75 RAB9A (0.49) KMT2A
SCHEMBL10801943 0.73 PIM1 (0.56) PIM1KDM4EKMT2ALMNATP53
SCHEMBL11740084 0.73 KMT2A (0.52) PIM1GPR35KDM4EKMT2AHCAR2
SCHEMBL5773853 0.73 MAPT (0.38) KDM4EKMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1472241-A4 CYTOPROTECTIVE BENZOFURAN DERIVATIVES GALILEO PHARMACEUTICALS INC (US) 2005-06-29 EP claimed
EP-1472241-A1 CYTOPROTECTIVE BENZOFURAN DERIVATIVES Galileo Pharmaceuticals, Inc. (US) 2004-11-03 EP claimed
US-6653346-B1 Amtiischemic and antiinflammatory agents GALILEO PHARMACEUTICALS, INC. 2003-11-25 US claimed
WO-2003066618-A1 CYTOPROTECTIVE BENZOFURAN DERIVATIVES GALILEO PHARMACEUTICALS, INC. (US) 2003-08-14 WO claimed
US-7078541-B2 Benzofuran derivatives GALILEO PHARMACEUTICALS, INC. (US) 2006-07-18 US disclosed
EP-1472241-A4 CYTOPROTECTIVE BENZOFURAN DERIVATIVES GALILEO PHARMACEUTICALS INC (US) 2005-06-29 EP disclosed
WO-2005027900-A1 BENZOFURAN DERIVATIVES GALILEO PHARMACEUTICALS, INC. (US) 2005-03-31 WO disclosed
EP-1472241-A1 CYTOPROTECTIVE BENZOFURAN DERIVATIVES Galileo Pharmaceuticals, Inc. (US) 2004-11-03 EP disclosed
US-20040063975-A1 Benzofuran derivatives EDISON PHARMACEUTICALS, INC. 2004-04-01 US disclosed
US-6653346-B1 Amtiischemic and antiinflammatory agents GALILEO PHARMACEUTICALS, INC. 2003-11-25 US disclosed
WO-2003066618-A1 CYTOPROTECTIVE BENZOFURAN DERIVATIVES GALILEO PHARMACEUTICALS, INC. (US) 2003-08-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040063975-A1 Benzofuran derivatives NDUFAB1, AIFM1, NDUFAF1 PIM1 3275/4885GPR35 2828/4885KDM4E 1972/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.